Kezar Life Sciences (KZR) Stock Price, News & Analysis

Company Overview

Kezar Life Sciences is a clinical-stage biotechnology company focused on the discovery and development of novel small-molecule therapies that modulate the innate immune system. The company’s research centers on selective inhibition of the immunoproteasome, a key protein complex involved in antigen processing and secretion of inflammatory cytokines. By targeting this pathway, Kezar aims to address unmet medical needs in autoimmune and inflammatory diseases with high specificity and a favorable safety profile.

The company’s lead development candidate, KZR-616, is a selective immunoproteasome inhibitor being evaluated in multiple clinical trials for autoimmune conditions such as systemic lupus erythematosus, lupus nephritis, polymyositis and dermatomyositis. Early clinical data have demonstrated reductions in inflammatory biomarkers and improvements in disease activity scores. Kezar’s pipeline also includes preclinical programs exploring complementary immunoproteasome and innate immune targets, with the goal of expanding treatment options across a range of inflammatory disorders.

Founded in 2015 and headquartered in South San Francisco, Kezar Life Sciences was established with venture backing to advance precision immunology research. The company operates under the leadership of CEO Heather Franklin, whose prior experience spans oncology and immunology drug development. Kezar’s management team combines expertise in medicinal chemistry, immunology, and clinical development to drive its product candidates through late-stage studies.

Kezar Life Sciences conducts its clinical trials primarily within the United States, with additional study sites in Europe and Asia through strategic collaborations. The company maintains partnerships with academic research centers and industry organizations to facilitate patient enrollment, assay development and biomarker analysis, positioning Kezar to deliver targeted therapies to patients globally.

Key Stats

• Today's Range: $7.27 to $7.47
• 50-Day Range: $6.20 to $7.45
• 52-Week Range: $3.53 to $7.55
• Volume: 616,000 shs
• Average Volume: 125,152 shs
• Market Capitalization: $53.86 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.00
• Consensus Rating: Reduce

Kezar Life Sciences Stock Analysis - MarketRank™

Kezar Life Sciences scored higher than 15% of companies evaluated by MarketBeat, and ranked 810th out of 866 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Reduce

Consensus Rating

Kezar Life Sciences has received a consensus rating of Reduce. The company's average rating score is 1.67, and is based on no strong buy ratings, no buy ratings, 4 hold ratings, and 2 sell ratings.

Downside Risk

Kezar Life Sciences has a consensus price target of $6.00, representing about 17.7% downside from its current price of $7.29.

Amount of Analyst Coverage

Kezar Life Sciences has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Kezar Life Sciences is -1.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Kezar Life Sciences is -1.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Kezar Life Sciences has a P/B Ratio of 0.76. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.37% of the float of Kezar Life Sciences has been sold short.

Short Interest Ratio / Days to Cover

Kezar Life Sciences has a short interest ratio ("days to cover") of 2.28, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Kezar Life Sciences has recently increased by 4.56%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Kezar Life Sciences does not currently pay a dividend.

Dividend Growth

Kezar Life Sciences does not have a long track record of dividend growth.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: -0.25

News Sentiment

Kezar Life Sciences has a news sentiment score of -0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Kezar Life Sciences this week, compared to 1 article on an average week.

Company Ownership

• Score: 1.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Kezar Life Sciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

10.40% of the stock of Kezar Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

67.90% of the stock of Kezar Life Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/11/2026
• Today: 5/23/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:KZR
• CIK: 1645666
• Web: www.kezarlifesciences.com
• Phone: (650) 822-5600
• Fax: N/A
• Employees: 60
• Year Founded: 2015

Price Target and Rating

• Average Price Target for Kezar Life Sciences: $6.00
• High Price Target: $7.00
• Low Price Target: $5.00
• Potential Upside/Downside: -17.7%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.67
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($6.17)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$56.03 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -55.42%
• Return on Assets: -47.87%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 11.52
• Quick Ratio: 11.52

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $9.57 per share
• Price / Book: 0.76

Miscellaneous

• Outstanding Shares: 7,388,000
• Free Float: 6,701,000
• Market Cap: $53.86 million
• Optionable: Not Optionable
• Beta: 0.40